Click on headlines below to download research
Selincro, as nalmefene is branded, has been filed with the EMA. It is the first alcohol dependence therapy that does not require abstinence and can be…
Biotie is focused on progressing the clinical development of its pipeline of differentiated drug programmes in CNS, and on business development. Pipeline…
Merck Serono’s return of global rights to the Phase III Parkinson’s programme, safinamide, is likely to lead to a renegotiation of the terms…